Increasing local levels of IGF-I mRNA expression using adenoviral vectors does not alter oligodendrocyte remyelination in the CNS of aged rats - PubMed (original) (raw)

Increasing local levels of IGF-I mRNA expression using adenoviral vectors does not alter oligodendrocyte remyelination in the CNS of aged rats

M T O'Leary et al. Mol Cell Neurosci. 2002 Jan.

Abstract

IGF-I, a growth factor that contributes to developmental myelination, shows increased levels of expression within experimental models of remyelination. The pattern of IGF-I mRNA expression changes with the rate of remyelination, with peak levels of expression occurring earlier during rapid remyelination in young adult rats compared to the slower remyelination in old adult rats. In this study we have attempted to accelerate remyelination in old adult rats by using an IGF-expressing adenoviral vector (IGF-I-Ad) to bring forward the timing of peak level of IGF-I expression. Following injection of IGF-I-Ad into focal areas of lysolecithin-induced demyelination in the spinal white matter of old adult rats we created levels of IGF-I mRNA expression at 10 days that were considerably higher than those normally occurring at this time and more similar to those in young animals. However, despite the elevated levels of IGF-I mRNA expression there was no significant change in the extent of oligodendrocyte remyelination compared to saline controls or animals injected with an adenoviral vector expressing LacZ (NT-LacZ-Ad). There was a small increase in Schwann cell remyelination in IGF-I-Ad- and NT-LacZ-Ad-injected animals compared to saline controls. These results indicate that changing the levels of IGF-I directly within demyelinating lesions undergoing remyelination is not sufficient to alter remyelination and that the proremyelinating effects of systemically delivered IGF-I are unlikely to be due to direct effects on the oligodendrocyte lineage.

PubMed Disclaimer

Cited by

Multiple Sclerosis and Aging: The Dynamics of Demyelination and Remyelination.
Correale J, Ysrraelit MC. Correale J, et al. ASN Neuro. 2022 Jan-Dec;14:17590914221118502. doi: 10.1177/17590914221118502. ASN Neuro. 2022. PMID: 35938615 Free PMC article. Review.
Hormonal Regulation of Oligodendrogenesis II: Implications for Myelin Repair.
Breton JM, Long KLP, Barraza MK, Perloff OS, Kaufer D. Breton JM, et al. Biomolecules. 2021 Feb 16;11(2):290. doi: 10.3390/biom11020290. Biomolecules. 2021. PMID: 33669242 Free PMC article. Review.
Regulating Axonal Responses to Injury: The Intersection between Signaling Pathways Involved in Axon Myelination and The Inhibition of Axon Regeneration.
Rao SN, Pearse DD. Rao SN, et al. Front Mol Neurosci. 2016 Jun 8;9:33. doi: 10.3389/fnmol.2016.00033. eCollection 2016. Front Mol Neurosci. 2016. PMID: 27375427 Free PMC article. Review.
The role of growth factors as a therapeutic approach to demyelinating disease.
Huang Y, Dreyfus CF. Huang Y, et al. Exp Neurol. 2016 Sep;283(Pt B):531-40. doi: 10.1016/j.expneurol.2016.02.023. Epub 2016 Mar 22. Exp Neurol. 2016. PMID: 27016070 Free PMC article. Review.
Extracellular cues influencing oligodendrocyte differentiation and (re)myelination.
Wheeler NA, Fuss B. Wheeler NA, et al. Exp Neurol. 2016 Sep;283(Pt B):512-30. doi: 10.1016/j.expneurol.2016.03.019. Epub 2016 Mar 23. Exp Neurol. 2016. PMID: 27016069 Free PMC article. Review.

Increasing local levels of IGF-I mRNA expression using adenoviral vectors does not alter oligodendrocyte remyelination in the CNS of aged rats - PubMed (original) (raw)